PharmaEssentia Corporation
6446
Rang în acțiuni
#1440
PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing... PharmaEssentia Corporation is a biopharmaceutical firm dedicated to developing therapies for human ailments, serving both the Taiwanese and international markets. Its product portfolio prominently features Ropeginterferon alfa-2b, indicated for the management of various hematological conditions including chronic myelogenous leukemia, T-Cell leukemia, early myelofibrosis, polycythemia vera, and essential thrombocythemia. Beyond this, the company's pipeline includes TCRT, anti PD-1, PEG-cytokine X,Y, and novel checkpoint antibodies, all under development for solid tumors. A specific combination, P1101 + anti PD-1, is being explored for hepatocellular carcinoma, while PEG-GCSF addresses neutropenia. Fundamentally, its comprehensive research and development initiatives span key therapeutic areas such as hematology, infectious diseases, and oncology. Established in 1990, PharmaEssentia Corporation maintains its headquarters in Taipei, Taiwan.
Preț acțiune
$36.89
Capitalizare de piață
$15.25B
Schimbare (1 zi)
-1.28%
Schimbare (1 an)
144.12%
Țară
TW
Tranzacționează PharmaEssentia Corporation (6446)
Categorie
Healthcare
Raport P/S pentru PharmaEssentia Corporation (6446)
Raport P/S la data de October 2026 TTM: 23.96
Conform celor mai recente rapoarte financiare și prețului acțiunilor PharmaEssentia Corporation, raportul P/S actual (TTM) este 23.96. La sfârșitul anului 2023, compania avea un P/S de 22.06.
Istoricul raportului P/S pentru PharmaEssentia Corporation din 2010 până în 2026
Raport P/S la sfârșitul fiecărui an
| An | Raport P/S | Schimbă |
|---|---|---|
| 2026 (TTM) | 23.96 | 16.52% |
| 2024 | 20.56 | -6.80% |
| 2023 | 22.06 | -53.07% |
| 2022 | 47.01 | -58.98% |
| 2021 | 114.59 | 181.19% |
| 2020 | 40.75 | -46.81% |
| 2019 | 76.61 | -94.54% |
| 2018 | 1.40K | -81.75% |
| 2017 | 7.68K | 27.57% |
| 2016 | 6.02K | 95.48% |
| 2015 | 3.08K | 61.64% |
| 2014 | 1.91K | 276.50% |
| 2013 | 506.34 | -45.75% |
| 2012 | 933.30 | -41.98% |
| 2011 | 1.61K | 237.00% |
| 2010 | 477.29 | 0.00% |
Raport P/S pentru companii similare sau competitoare
| Companie | Raport P/S | Diferență raport P/S | Țara |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 7.06 | -70.54% |
IN
|
